Human EBV EA IgG ELISA kit is designed for measuring in-vitro quantitative amounts of human IgG antibodies against Epstein–Barr virus early antigen (EBV EA IgG) in serum or plasma. This assay has a minimum analytical sensitivity limit of 1.37 U/ml.
Epstein–Barr virus (EBV) is a member of the herpes family of viruses, it can also be called human herpesvirus 4 (HHV-4). The majority of the infections for EBV occur via oral transfer of saliva or genital secretion, many of these viral infections have also been strongly associated to a number of different autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren’s syndrome and dermatomyositis. The detection of early antigen (EA) is quite often used to indicate an active infection, since EBV EA is linked to many acute phase illness and majority of these become undetectable after 3-6 months. Laboratory procedure such as ELISA assays and blood test are particularly useful in distinguishing a recent from a past EDV infection.
EBV EA IGG ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- EBV Early Antigen coated microtiter strips.
- Calibrator A (Negative Control).
- Calibrator B (Cut-Off Standard).
- Calibrator C (Weak Positive Control).
- Calibrator D (Positive Control).
- Enzyme Conjugate.
- TMB Substrate.
- Stop Solution.
- Sample Diluent.
- Washing Buffer (10x).
The minimum detection sensitivity level of IgG antibodies to Epstein–Barr virus early antigen (EBV EA-IgG) using current human EBV EA IgG ELISA kit was 1.37 U/ml. The dynamic range for this assay is 1.0 – 150.0 U/ml.
– EBV EA ELISA: IgG
– Intra-Assay-Precision: 8.6 %
– Inter-Assay-Precision: 6.2 %
– Inter-Lot-Precision: 4.3 – 6.6 %
– Analytical Sensitivity: 1.37 U/mL
– Recovery: 95 – 106 %
– Linearity: 78 – 117 %
– Cross-Reactivity: No cross-reactivity to Herpes, Measles, Mumps and Varicella.
– Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL.
– Clinical Specificity: 94 %
– Clinical Sensitivity: 100 %
- Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev. (2003) 4 (2): 113-8. Tiwawech D., et al.
- Enzyme-linked immunosorbent assay for IgG antibodies to Epstein-Barr virus-associated early antigens and viral capsid antigen. J Immunol Methods. (1984) 67 (2): 225-33. Dölken G., et al.
- Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology. J Med Virol. (1994) 43 (3): 238-44. Andersson A., et al.
- Antibodies to Epstein-Barr virus-induced early antigens in blood donors. Acta Virol. (1989) 33 (4): 344-8. Wohlrabe P., et al.
- Full Name: EBV EA (Early Antigen) IgG ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: 1.37 U/ml